Purpose To evaluate the clinical outcomes following bilateral implantation of PanOptix intraocular lens (IOL). Methods This study included consecutive patients scheduled to undergo cataract or refractive lens exchange surgery between… Click to show full abstract
Purpose To evaluate the clinical outcomes following bilateral implantation of PanOptix intraocular lens (IOL). Methods This study included consecutive patients scheduled to undergo cataract or refractive lens exchange surgery between October 2017 and June 2018 at two centers. Manifest refraction, uncorrected distance visual acuity (UDVA), uncorrected intermediate visual acuity (UIVA, 60 cm) and uncorrected near visual acuity (UNVA, 40 cm), defocus curves, presence of dysphotopsia, need for spectacles, presence of posterior capsule opacification and visual function were evaluated at 6 months after surgery. Results The IOL was implanted in 138 eyes of 69 patients. The mean binocular UDVA was 0.02 ± 0.05 logMAR, UIVA 0.06 ± 0.07 logMAR and UNVA 0.05 ± 0.07 logMAR. Defocus curve showed two peaks at 0.00 D and − 1.50 D. Complete spectacle independence was reported in 94.2% of the patients. The mean VF-14 test result was 97.7 ± 2.2 (93.2–100). Only one patient (1.4%) reported seeing bothersome halos. The presence of posterior capsule opacification was noted in seven eyes (10%), whereas Nd:Yag capsulotomy was required only in one eye. Conclusions This trifocal IOL provided excellent visual outcomes at all distances with high spectacle independence and patient’s satisfaction.
               
Click one of the above tabs to view related content.